Dallas, TXNCT04677413Now EnrollingIRB Ready

Rectal Cancer Clinical Trial in Dallas, TX

Access cutting-edge rectal cancer treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.

Sponsored by University of Texas Southwestern Medical Center

Quick Self-Assessment

See if you qualify for this Dallas location

Preparing your pre-screening questions…

Expert Care in Dallas

Access rectal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related rectal cancer treatment provided free

Apply for This Dallas Location

Check if you qualify for this rectal cancer clinical trial in Dallas, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Dallas

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Dallas site if eligible
  4. 4Begin participation

About This Rectal Cancer Study in Dallas

The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a prolonged interval, at escalated doses and with concurrent chemotherapy may be feasible and allow for improved clinical response.

Sponsor: University of Texas Southwestern Medical Center

Who Can Participate

Inclusion Criteria

At least 18 years of age. Both men and women and members of all races and ethnic groups will be included.
Willing and able to provide written informed consent
Pathologic diagnosis of rectal adenocarcinoma
T3-4 and/or N+ disease per AJCC 8th edition
No prior treatment for rectal adenocarcinoma
Eastern Cooperative Group (ECOG) performance status of 0-2.
Laboratory values supporting acceptable organ and marrow function within 30 days of eligibility confirmation. Defined as follows:
WBC ≥ 3,000/mL;
ANC WBC ≥ 1,000/mL;
PLT ≥ 75,000/mL;
T Bili ≤ 1.5 x upper limit of normal (ULN);
AST/ALT ≤ 2.5 x ULN;
Creatinine not above ULN, or creatinine clearance \>50 mL/min/1.73 m\^2 for participants with creatinine levels above institutional normal.
All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) starting with the first dose of study therapy through 90 days after the last dose of study drugs. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

Exclusion Criteria

Distant nodal disease (retroperitoneal nodes) including inguinal nodes, or any metastatic disease by CT.
Prior RT to the pelvis.
Uncontrolled comorbid illness or condition including congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness that would limit compliance with the study requirements.
Psychiatric illness/social situations that would limit consenting and compliance with study requirements.
Participants who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT04677413) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Rectal Cancer Treatment Options in Dallas, TX

If you're searching for rectal cancer treatment options in Dallas, TX, this clinical trial (NCT04677413) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced rectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all rectal cancer clinical trials near you to find additional studies recruiting in your area.

More Colorectal Cancer Trials in Dallas, TX

See all colorectal cancer clinical trials recruiting in Dallas — not just this study.

Browse Colorectal Cancer Trials in Dallas →

Browse More Trials by Condition

Colorectal Cancer TrialsAll Conditions →

Ready to Join in Dallas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Dallas, TX